tbuckley/cabot-search huggingface dataset:
Knowing Ron
Authors: Phyllis L. Spechko
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0001 ERAP-1 Haplotype Influences Clinical Phenotype but not Cytokine Expression in Ankylosing Spondylitis
Authors: J. Nossent, S.S. Johnsen, G. Bakland
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Endoplasmic reticulum aminopeptidase-1 (ERAP1) is an enzyme that trims peptides for presentation on the MHC class I complex and also contributes to cytokine receptor cleaving. ERAP1 gene variants affect the susceptibility for HLA B27 positive Ankylosing Spondylitis (AS), but the impact of ERAP1 polymorphisms on AS phenotype is less well characterized. <h3>Objectives</h3> Toinvestigate the relation between two loss of function variants (rs27044 (C-G) and rs30187 (A-T)) that lead to decreased peptide trimming activity by ERAP1 and the broad phenotype in AS including bioactivity of inflammatory cytokines <h3>Methods</h3> Cross sectional and longitudinal cohort study of patients with established AS (n=334, 90% B27 +, mean age at study 45 years) for whom clinical data and biological samples were collected during a research visit. Genotyping was done by Taqman RT-PCR with IL-6 and TNF levels determined by sandwich ELISA. Associations between genotypes, clinical and serological findings were analyzed using SNPstats <h3>Results</h3> Allele and genotype distribution for both SNPs was similar in HLA B27+ and B27– patients. Both SNPs were in strong linkage disequilibrium and formed three common haplotypes (C/C 0.65, G/T 0.30, C/T 0.04). Haplotype C/T was more frequent in HLA B27 + patients (OR 3.2, p=0.038), and carried a lower risk for extra-spinal manifestations (OR 0.2, p=0.03), especially uveitis (OR 0.32, p=0.03), elevated CRP (OR 0.26 p=0.04) and elevated ESR (OR 0, p=0.03). There was no effect of ERAP-1 haplotypes on cytokine levels or maior outcomes (death or disability) during eight years of follow-up. <h3>Conclusions</h3> ERAP-1 rs27044/rs30187 haplotype C/T associates strongly with HLA-B27 and reduces the risk of extra-spinal disease and systemic inflammation in patients with AS. However ERAP-1 haplotype has no direct bearing on serum IL-6 or TNF-levels. <h3>Acknowledgements</h3> The authors wish to thank Kirsten Nilsen at the Rheumatology Research Laboratory for excellent technical support and drs J. Gran, A. Becker-Merok, E,. Bakke, B. Nordvag for help with data collection. Supported by an unrestricted investigator grant to JCN from Abbott Norway AS (grantnr. IMM 09- 0054) and a grant from Odd Fellow Norway Medical Research Fund. <h3>Disclosure of Interest</h3> None declared
SP0070 GCA and PMR: Steroids or Bust?
Authors: C. Dejaco
Journal: Annals of the Rheumatic Diseases (2015)

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are treated with oral glucocorticoids (GC) resulting in a rapid and complete response of symptoms in most cases. Early diagnosis and treatment of GCA is essential given that blindness and other ischemic complications usually occur before initiation of GC therapy. Flares are common in PMR and GCA; duration of GC therapy usually lasts 1-3 years. In some cases, treatment may even be lifelong. GC related adverse events (AEs) frequently occur in PMR and GCA leading to a restriction of patients9 quality of life and causing high economic burden. Immunosuppressive agents are thus warranted for treatment of PMR and GCA, particularly in patients with comorbidities that may be exaggerated by GC therapy and/or in case of risk factors for prolonged treatment being present. Methotrexate (MTX) has been recommended by the British Society of Rheumatology (BSR) for patients with relapsing PMR and GCA whereas EULAR suggests to consider MTX for every GCA case. Limited evidence is available for other conventional DMARDs such as azathioprine and leflunomide; these agents may thus be considered for treatment resistant cases. The role of biological agents is unclear: studies on infliximab failed the primary endpoint in PMR and GCA whereas etanercept led to a reduction of the cumulative GC dose in a study of GCA patients requiring ≥10mg/day oral prednisone to maintain remission. Tocilizumab yielded promising results in case reports/series of PMR and GCA, and this drug is currently being studied in a placebo controlled trial of GCA (GiACTA). In this session, we will discuss the role of steroid sparing agents in the treatment of PMR and GCA presenting a clinical case as well as current evidence from randomized controlled trials. <h3>Disclosure of Interest</h3> None declared
GRADUATE MEDICAL EDUCATION IN THE UNITED STATES
Authors: J W Cole
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Case 22-1970
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Edwin O. Wheeler, Jerry Harris
Journal: New England Journal of Medicine (1970)

Presentation of Case First admission. A forty-nine-year-old male school teacher was admitted to the hospital because of dyspnea.Five years previously he had the onset of intermittent bandlike precordial pain, with radiation to both shoulders and down the left arm; the pain was brought on by exercise and relieved by rest and nitroglycerin. Two years later he was admitted to another hospital because of acute myocardial infarction; he returned to work four months later. Four months before entry he was readmitted to the hospital because of another acute myocardial infarction. A regimen of digitalis, warfarin and ethacrynic acid was . . .
Comparative efficacy of tofisopam and placebo
Authors: H L Goldberg, R J Finnerty
Journal: American Journal of Psychiatry (1979)

Tofisopam is a new agent marketed in Europe as a minor tranquilizer. The authors conducted a 4-week double-blind trial of this drug compared with placebo in 57 outpatients with anxiety and depression. They found that according to physician ratings and patient self-ratings tofisopam was an effective anxiolytic agent for subjects with anxiety and depression. Twenty-one percent of the patients receiving tofisopam and 10% of those receiving placebo reported side effects. The drug was especially effective in the treatment of somatic difficulties.
Anticipatory Guidance
Authors: Marjorie S Rosenthal
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EUPHORIA VS. EUTHANASIA.
Authors: Jennifer Reiling
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic identification of thiosulfate sulfurtransferase as an adipocyte-expressed antidiabetic target in mice selected for leanness
Authors: Nicholas M Morton, Jasmina Beltram, Roderick N Carter, Zoi Michailidou, Gregor Gorjanc, Clare McFadden, Martin E Barrios-Llerena, Sergio Rodriguez-Cuenca, Matthew T G Gibbins, Rhona E Aird, José Maria Moreno-Navarrete, Steven C Munger, Karen L Svenson, Annalisa Gastaldello, Lynne Ramage, Gregorio Naredo, Maximilian Zeyda, Zhao V Wang, Alexander F Howie, Aila Saari, Petra Sipilä, Thomas M Stulnig, Vilmundur Gudnason, Christopher J Kenyon, Jonathan R Seckl, Brian R Walker, Scott P Webster, Donald R Dunbar, Gary A Churchill, Antonio Vidal-Puig, José Manuel Fernandez-Real, Valur Emilsson, Simon Horvat
Journal: Nature Medicine (2016)
SAT0238 Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study
Authors: C. Webers, I. Essers, S. Ramiro, C. Stolwijk, R. Landewé, D. van der Heijde, F. van den Bosch, M. Dougados, A. van Tubergen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In ankylosing spondylitis (AS), gender-attributable differences have been reported with respect to clinical and radiographic outcome. However, longitudinal studies exploring gender-attributable differences in the outcome of AS are scarce and/or have limited follow-up. <h3>Objectives</h3> To investigate gender-attributable differences regarding clinical outcome (disease activity, physical function and quality of life (QoL)) and radiographic damage in patients with AS over time. <h3>Methods</h3> Data from the Outcome in AS International Study were used. Disease activity was assessed by the Bath AS Disease Activity Index (BASDAI), C-reactive protein (CRP), and AS Disease Activity Score with CRP (ASDAS-CRP); physical function by Bath AS Functional Index (BASFI); QoL by the Short Form-36 Physical and Mental Component Summary scores (SF-36PCS and SF-36MCS), ASQoL and EuroQoL; and radiographic damage by the modified Stoke AS Spine Score (mSASSS). Cross-sectional comparative analyses were done at baseline. Next, separate models were created to assess gender-attributable differences on each outcome measure over time using generalized estimating equations. All analyses were performed in the total population and in those patients who completed the total 12 years of follow-up. <h3>Results</h3> 216 patients (154 (72.3%) males, mean age 43.6 years (SD 12.7), symptom duration 20.5 years (SD 11.8), mean follow-up duration 8.3 years (SD 4.1)) were included. At baseline, male compared with female patients had lower self-reported disease activity (BASDAI 3.2 vs. 3.9, p=0.03) but more radiographic damage (mSASSS 13.8 vs. 6.5, p=0.02). No significant gender-attributable differences in other clinical parameters were found. In multivariable analysis using separate models, male gender was significantly associated with a better ASQoL (B=-1.18, 95% confidence interval (CI) -2.17 to -0.20, p=0.02), with a better SF-36MCS (B =5.84, 95% CI 2.21 to 9.48, p&lt;0.01) and with a higher mSASSS over time (B=8.24, 95%CI 4.38 to 12.09, p&lt;0.01). Similar results were found for the 12-year completers. <h3>Conclusions</h3> In this prospective cohort study, no gender-attributable differences were found for disease activity (measured with ASDAS) or physical function over time. However, male patients had more severe radiographic damage over time. Furthermore, and independently of radiographic damage, male patients had a better QoL over time. It is likely that gender differences in AS are determined by both biological and psychological factors, and that male and female patients differ in the way they cope with pain and disability. <h3>Disclosure of Interest</h3> None declared
PTH-061 Anti-tumour necrosis factor-alfa drug monitoring in paediatric inflammatory bowel disease
Authors: R Muhammed, T Wong, W Haller, R Bremner, S Protheroe
Journal: Gut (2015)

<h3>Introduction</h3> The lack of familiarity with the Commercial assays to measure anti-Tumour Necrosis Factor-alfa (TNF) drug and antibody levels and the cost implication has limited their widespread clinical use. <h3>Method</h3> We have done a retrospective analysis of anti TNF-alfa drug monitoring in patients with IBD over 12 months. We have correlated anti-TNF-alfa drug levels with the presence of anti-TNF antibody, concomitant treatment with Azathioprine and the clinical remission status. We have also looked at the cost effectiveness of anti-TNF-alfa drug monitoring. <h3>Results</h3> 89 anti TNF drug and antibody levels were done in 47 patients receiving Infliximab in the last twelve months (41 patients had Crohn’s disease, 4 had ulcerative colitis and 2 had IBD unclassified). 14 patients (30%) had below therapeutic levels of Infliximab and all were receiving Infliximab 5 mg/Kg dose. 12 of these patients had Crohn’s disease and all these 12 patients were on concomitant treatment with Azathioprine. 7 of these patients (58%) had anti-Infliximab antibody positivity. Out of the 12 Crohn’s disease patients with low Infliximab levels, 3 were in deep remission with mucosal healing and these three patients were positive for anti-Infliximab antibodies. In these 3 patients treatment with Infliximab was stopped. Of the 12 patients with Crohn’s disease and low levels of Infliximab, 9 (75%) were not in clinical remission. 4 of these patients had antibody positivity and dose escalation to 10 mg/kg achieved clinical remission in only one of these patients. 5 Crohn’s disease patients who were not in clinical remission with low Infliximab levels and no anti Infliximab antibodies achieved clinical remission with Infliximab dose increase to 10 mg/kg. 4 patients had Infliximab concentrations higher than the therapeutic range and all these patients were on 10mg/kg dose. 15 patients (32%) had anti-Infliximab antibody positivity and all these patients had Crohn’s disease. 7 of these patients had low Infliximab levels, 2 had high Infliximab levels (on 10 mg/kg dose) and 6 had Infliximab levels in therapeutic range. 14 of these patients were receiving concomitant Azathioprine. Out of these 15 patients, 9 were in clinical remission. Overall cost savings of about 9000 GBP per year were achieved by Infliximab dose adjustment, even after considering the cost of these investigations and the cost of increased dose of Infliximab in some patients. <h3>Conclusion</h3> Anti-TNF-alfa drug level and antibody monitoring are very useful and cost effective in the management of children with inflammatory bowel disease <h3>Disclosure of interest</h3> R. Muhammed Grant/ Research Support from: MSD immunology, Abbvie, Tillotts Pharma, Consultant for: Abbvie, Speaker Bureau of: Abbvie, MSD Immunology, T. Wong: None Declared, W. Haller: None Declared, R. Bremner: None Declared, S. Protheroe Consultant for: MSD Immunology, Conflict with: MSD Immunology.
OP0192 S100 Proteins in Dendritic Cells Regulate Inflammatory Processes
Authors: D. Popp, B. Petersen, F. Rühle, J. Roth
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> S100A8 and S100A9, also known as myeloid-related protein-8 (MRP8) and MRP14, are widely used as biomarkers of disease activity in juvenile idiopathic arthritis. On a molecular level these proteins function as damage-associated molecular pattern molecules (DAMPs), which amplify inflammation via Toll-like receptor-4 (TLR-4) activation. Released from activated phagocytes or necrotic cells the physiologically relevant S100A8/A9 heterodimers stimulate surrounding cells in order to promote pro-inflammatory processes in innate immunity. Adaptive immunity is believed to be enhanced by these molecules via activation of dendritic cells (DCs). Interestingly, recent studies show an additional regulatory effect of S100 proteins on DCs upon prolonged exposure (Petersen et al. EMBO-J 2013). <h3>Objectives</h3> The aim of this study is to decipher the S100 protein dependent molecular mechanisms in dendritic cells which enforce aggravation or attenuation of inflammation. <h3>Methods</h3> Human monocyte derived or murine bone marrow derived DCs are differentiated with or without exposure to S100A8 for six days prior to activation with LPS. After characterization and determination of the activation status using flow cytometry, the ability of these cells to induce T-cell proliferation is investigated in an autologous, antigen-specific or allogenic fashion. To identify the molecular mechanisms leading to the observed phenotype the mRNA expression of human DCs in various stages of differentiation was screened by genome-wide gene expression arrays. <h3>Results</h3> In a model of allergic contact dermatitis S100A9 deficient mice developed elevated inflammatory responses compared to wild type mice. We could demonstrate that prolonged exposure of myeloid progenitor cells to S100 proteins blocks DC differentiation and antigen presentation resulting in a reduced OT1 and OT2 T-cell response. Human S100A8/A9 shows a similar regulatory impact on monocyte-derived DCs (moDCs), since early DC differentiation and subsequent antigen-presentation is inhibited by S100A8 as well, leading to altered T-cell responses associated with decreased proliferation and enhanced IL-10 secretion. Gene expression analysis of developing DCs indicates vast changes in prominent immune modulatory pathways like JAK/STAT, NOD, RIG-I and TLR signalling. In addition, cell adhesion and antigen presentation seems to be affected by metabolic changes (e.g. PPAR-γ regulated fatty acid biosynthesis) as well as surface expression of antigen presenting molecules like HLA and CD1c. <h3>Conclusions</h3> Taken together, our results represent a novel regulatory mechanism of innate immunity to prevent overwhelming immune responses. <h3>Disclosure of Interest</h3> None declared
Early and Favourable Immune Reconstitution After Unmanipulated Haploidentical Stem Cell Transplantation With High Dose Post-Transplant Cyclophosphamide Regardless Intensity Of Conditioning Regimen
Authors: Isabel Gonzalez-Gascon y Marin, Ana María Pérez-Corral, Jorge Gayoso, Javier Anguita, Ana Carolina Franco, Cristina Pascual, Mi Kwon, David Serrano, Pascual Balsalobre, Ismael Buno, Carolina Martínez-Laperche, Elisabeth Sarmiento, Jose Luis Diez-Martin
Journal: Blood (2013)
A language-cultural course for foreign psychiatric residents
Authors: G K Arthur, R Brooks, M L Long
Journal: American Journal of Psychiatry (1979)

Foreign medical graduates are an important component of the health care system in the United States. All foreign medical graduates have acculturation problems, but they are especially aggravating among foreign psychiatric residents. These difficulties affect the personal lives of the foreign residents as well as crucial teacher-student and doctor-patient relationships. The authors report on an effort to further define these problems in a residency program and their systematic attempts to solve them by offering a special course. The program they describe benefitted not only the foreign residents but their families and the residency program itself.
Splenomegaly With Excess Numbers of Kurloff Cells in Guinea Pigs Treated With Stilbestrol&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Eli M. Nadel, M.D.
Journal: JNCI Journal of the National Cancer Institute (1952)

Splenomegaly With Excess Numbers of Kurloff Cells in Guinea Pigs Treated With Stilbestrol Get access Eli M. Nadel, M.D. Eli M. Nadel, M.D. Laboratory of Pathology, National Cancer Institute3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 3, December 1952, Pages 605–617, https://doi.org/10.1093/jnci/13.3.605 Published: 01 December 1952 Article history Received: 23 April 1952 Published: 01 December 1952
Lymphoedema is a potential sequela of kaposiform haemangioendothelioma
Authors: A. Hammill, P. Mobberley-Schuman, D. Adams
Journal: British Journal of Dermatology (2016)

We read the recent letter by Boccara et al. with great interest. They describe the case of a single infant with Kaposiform hemangioendothelioma (KHE) complicated by Kasabach-Merritt Phenomenon (KMP) who was successfully treated with sirolimus and developed lymphoedema of the affected limb 9 months into therapy. They do not describe any further steps taken at that time; it would be important to know if they adjusted dosing or held sirolimus, and how this affected the lymphoedema. They go on to speculate that lymphoedema was the result of the sirolimus therapy itself.

This article is protected by copyright. All rights reserved.